Otsuka (OTCMKTS:OTSKY) Sets New 1-Year High – Still a Buy?

Shares of Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) hit a new 52-week high during trading on Thursday . The company traded as high as $36.70 and last traded at $36.4725, with a volume of 10220 shares traded. The stock had previously closed at $35.45.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. The Goldman Sachs Group cut shares of Otsuka from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, February 27th. Morgan Stanley upgraded Otsuka to an “overweight” rating in a report on Friday, January 23rd. Zacks Research upgraded Otsuka from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, UBS Group raised Otsuka to a “hold” rating in a research note on Tuesday, January 27th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Otsuka has a consensus rating of “Hold”.

Otsuka Trading Down 3.6%

The company’s 50 day simple moving average is $34.00 and its two-hundred day simple moving average is $30.64. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67. The company has a market cap of $38.21 billion and a PE ratio of 15.01.

Otsuka (OTCMKTS:OTSKY) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.43 by $0.16. The firm had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.78 billion. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. As a group, sell-side analysts anticipate that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.86 EPS for the current fiscal year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.